Innovent Biologics, Inc. 1801.HK Stock
Innovent Biologics, Inc. Price Chart
Innovent Biologics, Inc. 1801.HK Financial and Trading Overview
Innovent Biologics, Inc. stock price | 35.9 HKD |
Previous Close | 33.95 HKD |
Open | 34.5 HKD |
Bid | 36.5 HKD x 0 |
Ask | 36.7 HKD x 0 |
Day's Range | 34.1 - 37 HKD |
52 Week Range | 21.2 - 47.95 HKD |
Volume | 11.2M HKD |
Avg. Volume | 7.2M HKD |
Market Cap | 56.31B HKD |
Beta (5Y Monthly) | 0.194959 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.71 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 50.98 HKD |
1801.HK Valuation Measures
Enterprise Value | 46.16B HKD |
Trailing P/E | N/A |
Forward P/E | -44.7561 |
PEG Ratio (5 yr expected) | 0.47 |
Price/Sales (ttm) | 12.359119 |
Price/Book (mrq) | 5.2481055 |
Enterprise Value/Revenue | 10.13 |
Enterprise Value/EBITDA | -16.039 |
Trading Information
Innovent Biologics, Inc. Stock Price History
Beta (5Y Monthly) | 0.194959 |
52-Week Change | 26.20% |
S&P500 52-Week Change | 20.43% |
52 Week High | 47.95 HKD |
52 Week Low | 21.2 HKD |
50-Day Moving Average | 38.23 HKD |
200-Day Moving Average | 34.96 HKD |
1801.HK Share Statistics
Avg. Volume (3 month) | 7.2M HKD |
Avg. Daily Volume (10-Days) | 6.17M HKD |
Shares Outstanding | 1.53B |
Float | 1.32B |
Short Ratio | N/A |
% Held by Insiders | 10.86% |
% Held by Institutions | 49.33% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -47.82% |
Operating Margin (ttm) | -68.53% |
Gross Margin | 69.67% |
EBITDA Margin | -63.15% |
Management Effectiveness
Return on Assets (ttm) | -11.53% |
Return on Equity (ttm) | -20.69% |
Income Statement
Revenue (ttm) | 4.56B HKD |
Revenue Per Share (ttm) | 3.06 HKD |
Quarterly Revenue Growth (yoy) | -0.50% |
Gross Profit (ttm) | 3.17B HKD |
EBITDA | -2877757952 HKD |
Net Income Avi to Common (ttm) | -2179269888 HKD |
Diluted EPS (ttm) | -1.52 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 9.17B HKD |
Total Cash Per Share (mrq) | 5.97 HKD |
Total Debt (mrq) | 3.23B HKD |
Total Debt/Equity (mrq) | 30.09 HKD |
Current Ratio (mrq) | 3.288 |
Book Value Per Share (mrq) | 6.993 |
Cash Flow Statement
Operating Cash Flow (ttm) | -1918803968 HKD |
Levered Free Cash Flow (ttm) | -2475026944 HKD |
Profile of Innovent Biologics, Inc.
Country | Hong Kong |
State | N/A |
City | Suzhou |
Address | 168 Dongping Street |
ZIP | 215123 |
Phone | 86 512 6956 6088 |
Website | https://www.innoventbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 5294 |
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Q&A For Innovent Biologics, Inc. Stock
What is a current 1801.HK stock price?
Innovent Biologics, Inc. 1801.HK stock price today per share is 35.9 HKD.
How to purchase Innovent Biologics, Inc. stock?
You can buy 1801.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Innovent Biologics, Inc.?
The stock symbol or ticker of Innovent Biologics, Inc. is 1801.HK.
Which industry does the Innovent Biologics, Inc. company belong to?
The Innovent Biologics, Inc. industry is Biotechnology.
How many shares does Innovent Biologics, Inc. have in circulation?
The max supply of Innovent Biologics, Inc. shares is 1.61B.
What is Innovent Biologics, Inc. Price to Earnings Ratio (PE Ratio)?
Innovent Biologics, Inc. PE Ratio is now.
What was Innovent Biologics, Inc. earnings per share over the trailing 12 months (TTM)?
Innovent Biologics, Inc. EPS is -0.71 HKD over the trailing 12 months.
Which sector does the Innovent Biologics, Inc. company belong to?
The Innovent Biologics, Inc. sector is Healthcare.
Innovent Biologics, Inc. 1801.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Large Cap NQEMKRLCGBPN | 1820.04 GBP 2327.71 USD |
<0.01
|
— — | 1820.04 GBP 2327.71 USD | 1820.04 GBP 2327.71 USD | — - | — — |
HANG SENG CHINA ENTERPRISES IND HSCE | 5857 HKD 748.89 USD |
-0.38
|
— — | 5795.02 HKD 740.97 USD | 5870.88 HKD 750.67 USD | — - | — — |
- {{ link.label }} {{link}}